ROS Therapeutics™ signs patent license agreement

Copenhagen, Denmark, July 3rd, 2018

ROS Therapeutics announces that a patent license agreement regarding molecules for the treatment of inflammatory diseases and cancer has been signed with the Technical University of Denmark (DTU). The patent portfolio, from which a lead candidate has been selected, covers several molecules/prodrugs that following activation by reactive oxygen species (ROS) releases the active moiety – either methotrexate or aminopterin - in inflammatory diseases and cancer.

 

Hanne Damgaard Jensen, CEO of ROS Therapeutics says:

“I am very excited about bringing the lead compound, targeted-MTX, out of its academic setting and into ROS Therapeutics to professionalise and speed-up the route to Clinical Proof of Concept. Having said that, DTU has functioned as an excellent incubator with competent leadership of the academic program by Mads Hartvig Clausen, Professor of Chemical Biology; and supported by the non-academic founders of ROS Therapeutics; Jon Bondebjerg and Christian Abildgaard Hansen. The spin out of the technology has been handled seamlessly by the licensing team at DTU.”

 

Christian Abildgaard Hansen, Inventor and CSO of ROS Therapeutics says:

“From getting the idea to this product about four years ago, and after watching the project mature at DTU, it is now culminating as a spin out from DTU. I am very happy about this progress and excited about the future. Our vision is to see this product reach patients who can benefit from this treatment and I look forward to participate in that journey.”

 

Marianne Thellersen, Senior Vice President of Innovation at DTU says:

”I have had the pleasure to follow this project and its development since the invention disclosure from the scientists at DTU’s Department of Chemistry and the submission of the patents. It is a promising technology that can benefit both patients and society. The fact that the researchers now are eager to engage in a spin out to further mature and hopefully later market a substance with fewer side effects is very positive. We encourage this and have actually supported the initiative all along by means of e.g. DTU’s own proof-of-concept fund. Grants from there have paved the way for additional tests and validation. The results look fine and will further strengthen ROS Therapeutics’ business case now where they must stand on their own feet and seek external funding. It is a good technology and a strong team, so I am confident that they will succeed and am only pleased to send off yet another durable start-up from DTU.”

 

 

— ooo —

 

 

About Targeted-MTX and Rheumatoid Arthritis
Targeted-MTX has potential to deliver the well understood clinical benefits of the established “cornerstone” treatment (MTX) for rheumatoid arthritis (RA) without the equally documented debilitating side-effects. We have developed a methotrexate prodrug that is designed for targeted release at the site of inflammation where high levels of ROS are present.

Targeted-MTX will initially be developed for the treatment of rheumatoid arthritis. RA is an autoimmune disease affecting approximately 0.5% of the world’s population. MTX is the most frequently prescribed medicine for this disease. Due to the narrow therapeutic margin and once-weekly dosing regimen, deaths and life threatening adverse effects are reported frequently due to incorrect dosing. Typical side effects such as nausea and vomiting also prevent a significant fraction of patients from tolerating the treatment.

 

About ROS Therapeutics ApS

ROS Therapeutics ApS was founded as a spin-out from DTU. It is a newly established privately owned pharmaceutical drug development company. Over the last few months, a very experienced and competent drug/business development team of Advisors and Internal Consultants has joined the company. ROS Therapeutics is presently going through a seed-financing round.

 

 

For further information, please visit www.ROStherapeutics.com.

 

Contact ROS Therapeutics:
Hanne Damgaard Jensen – CEO
Tel: + 45 40786888